KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Acquisitions: 2013-2015

  • Emergent BioSolutions' Acquisitions fell 46.37% to $650,000 in Q4 2015 from the same period last year, while for Dec 2015 it was $181.8 million, marking a year-over-year decrease of 11.43%. This contributed to the annual value of $827.7 million for FY2018, which is 604.43% up from last year.
  • As of Q4 2015, Emergent BioSolutions' Acquisitions stood at $650,000, which was down 46.37% from $1.2 million recorded in Q4 2014.
  • Emergent BioSolutions' Acquisitions' 5-year high stood at $178.2 million during Q1 2014, with a 5-year trough of $650,000 in Q4 2015.
  • Over the past 3 years, Emergent BioSolutions' median Acquisitions value was $1.8 million (recorded in 2013), while the average stood at $41.2 million.
  • Data for Emergent BioSolutions' Acquisitions shows a maximum YoY slumped of 46.37% (in 2015) over the last 5 years.
  • Emergent BioSolutions' Acquisitions (Quarterly) stood at $1.8 million in 2013, then slumped by 30.86% to $1.2 million in 2014, then tumbled by 46.37% to $650,000 in 2015.
  • Its last three reported values are $650,000 in Q4 2015, $1.2 million for Q4 2014, and $178.2 million during Q1 2014.